Ghassan K. Abou-Alfa
Baek-Yeol Ryoo
Sheng-Nan Lu
Chia-Jui Yen
Yin-Hsun Feng
Ho Yeong Lim
Francesco Izzo
Massimo Colombo
Debashis Sarker
Luigi Bolondi
Gina M. Vaccaro
William Proctor Harris
Zhendong Chen
Richard Hubner
Tim Meyer
John S. Bomalaski
Chen Chun Lin
Yee Chao
Li-Tzong Chen
Memorial Sloan Kettering Cancer Center, Port Washington, NY
The Chinese People's Liberation Army 81 Hospital, Nanjing, China
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
National Cheng Kung University Hospital, Tainan City, Taiwan
Chi Mei Medical Centre Yongkang, Tainan City, Taiwan
National Cancer Institute of Naples G.Pascale Foudation, Napoli, Italy
Maggiore Hospital, Milan, Italy
Department of Oncology, King's College Hospital, London, United Kingdom
Department of Medical and Surgical Sciences, University of Bologna and Center for Applied Biomedical Research (CRBA), S.Orsola-Malpighi Hospital, Bologna, Italy
Oregon Health and Science University, Portland, OR
University of Washington School of Medicine, Seattle, WA
2th Hospital of Anhui Medical Unive, Hefei, China
The Christie NHS Foundation TRUST, Manchester, United Kingdom
UCL Cancer Institute, University College London,, London, United Kingdom
Polaris Pharmaceuticals Inc, San Diego, CA
Chang Gung Medical Foundatio LK, Taoyuan, Taiwan
Taipei Veterans General Hospital, Taipei City, Taiwan
National Health Research Institutes (NHRI) - National Institute of Cancer Research, Taipei, Taiwan
China
Taiwan
Italy
United Kingdom
United States
N/A
Oncology (ONC)
Liver cancer
N/A
Pegargiminase
Sorafenib
Positive
Randomized
Placebo Control
III
NCT01287585
N/A
Final